Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trial
Authors:
- 1 November 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 24 (11) , 2037-2047
Abstract
Aims: To evaluate the contribution of baseline and longitudinal changes in cardiometabolic health (CMH) towards heart failure (HF) risk among adults with type 2 diabetes (T2D). Methods and results: Participants of the Look AHEAD trial with T2D and without prevalent HF were included. Adjusted Cox models were used to create a CMH score incorporating target levels of parameters weighted based on relative risk for HF. The associations of baseline and changes in the CMH score with risk of overall HF, HF with preserved (HFpEF) and reduced ejection fraction (HFrEF) were assessed using Cox models. Among the 5080 participants, 257 incident HF events occurred over 12.4 years of follow‐up. The CMH score included 2 points each for target levels of waist circumference, glomerular filtration rate, urine albumin‐to‐creatinine ratio, and 1 point each for blood pressure and glycated haemoglobin at target. High baseline CMH score (6–8) was significantly associated with lower overall HF risk (adjusted hazard ratio [HR], ref = low score (0–3): 0.31, 95% confidence interval [CI] 0.21–0.47) with similar associations observed for HFpEF and HFrEF. Improvement in CMH was significantly associated with lower risk of overall HF (adjusted HR per 1‐unit increase in score at 4 years: 0.80, 95% CI 0.70–0.91). In the ACCORD validation cohort, the baseline CMH score performed well for predicting HF risk with adequate discrimination (C‐index 0.70), calibration (chi‐square 5.53, p = 0.70), and risk stratification (adjusted HR [high (6–8) vs. low score (0–3)]: 0.35, 95% CI 0.26–0.46). In the Look AHEAD subgroup with available biomarker data, incorporating N‐terminal pro‐B‐type natriuretic peptide to the baseline CMH score improved model discrimination (C‐index 0.79) and risk stratification (adjusted HR [high (8–10) vs. low score (0–4)]: 0.18, 95% CI 0.09–0.35). Conclusions: Achieving target levels of more CMH parameters at baseline and sustained improvements were associated with lower HF risk in T2D.Keywords
Funding Information
- National Institutes of Health (DK 046204)
- National Heart, Lung, and Blood Institute
- National Institute of Nursing Research
- National Center on Minority Health and Health Disparities
- Centers for Disease Control and Prevention
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57136)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57149)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK56990)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57177)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57171)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57151)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57182)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57131)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57002)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57078)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57154)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57178)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57219)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57008)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57135)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK56992)
- Translational Science Center, Wake Forest University (GM104940)
- Translational Science Center, Wake Forest University (U54)
- Translational Science Center, Wake Forest University (P30DK072476)
- Indian Health Service
- Johns Hopkins University (M01RR02719)
- Massachusetts General Hospital
- Massachusetts Institute of Technology (M01RR01066)
- Harvard Catalyst (RR025758‐04)
- University of Colorado (M01RR00051)
- University of Tennessee, Knoxville (M01RR0021140)
- University of Pittsburgh (M01RR000056)
- U.S. Department of Veterans Affairs (M01RR01346)
This publication has 24 references indexed in Scilit:
- Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart StudyDiabetes Care, 2016
- Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million peopleThe Lancet Diabetes & Endocrinology, 2015
- PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease)JACC, 2013
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 DiabetesNew England Journal of Medicine, 2013
- A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive studyInternational Journal of Cardiology, 2013
- Impact of the Look AHEAD Intervention on NT‐pro Brain Natriuretic Peptide in Overweight and Obese Adults With DiabetesObesity, 2012
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) studyDiabetes & Vascular Disease Research, 2006
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetesControlled Clinical Trials, 2003